Funded Grants

The V Foundation’s grant making model ensures the most promising cancer research projects at state-of-the-art facilities around the country are funded. Cancer research grants are awarded to innovative researchers with the most cutting-edge ideas on how to improve cancer diagnosis methods, prevent cancer recurrences or defeat cancer. 100% of direct donations are used to fund projects we identify as the most likely to help those diagnosed with cancer.

2018
Jamie Spangler, Ph.D.
An immunoengineered cytokine-antibody fusion for targeted cancer therapy
Read More
2018
Adam Shlien, Ph.D.
Clinically relevant mutational signatures in aggressive childhood cancer
Read More
2018
Lewis Shi, M.D., Ph.D.
Metabolic checkpoints in anti-CTLA-4 and anti-PD-1 immunotherapies
Read More
2018
Paz Polak, Ph.D.
The genetic and epigenetic causes of BRCAness in breast cancer patients of...
Read More
2018
Mary Philip, M.D., Ph.D.
Organoid modeling of liver cancer-induced T cell dysfunction and reprogramming
Read More
2018
Selma Masri, Ph.D.
Linking the Circadian Clock and Cancer-Initiating Cells in the Intestine
Read More
2018
John Maciejowski, Ph.D.
Induction and mechanism of the prevalent APOBEC-associated mutational signatures in cancer
Read More
2018
Jens Lohr, M.D., Ph.D.
Exploiting blood biopsy to uncover mechanisms of drug resistance in multiple myeloma
Read More
2018
Pengda Liu, Ph.D.
Novel Functions for cGAS in cancer
Read More
2018
R. Coleman Lindsley, M.D., Ph.D.
Defining the role of BCOR mutations in endometrial carcinoma
Read More
2018
Daniel Lee, M.D.
Development of bispecific Chimeric Antigen Receptor T cells targeting tumor antigens and...
Read More
2018
Sita Kugel, Ph.D.
Identifying subtype-specific targeted therapies in pancreatic cancer
Read More
2018
H. Courtney Hodges, Ph.D.
Targeting SMARCA4 (BRG1) addiction in high-risk neuroblastoma
Read More
2018
Malachi Griffith, Ph.D.
Splicing regulatory aberrations and their role in tumor neoepitope creation
Read More
2018
Mingye Feng, Ph.D.
Programmed cell removal in cancer immunosurveillance
Read More
2018
Michael Deel, M.D.
Investigating co-activator TAZ as a regulator of PAX3-FOXO1, cancer cell stemness, and...
Read More